Medicamen Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has received EU approval for the product registration of Paracetamol from the Danish Medicine Authority in partnership with XGX Pharma, Denmark. This allows the company to register and market Paracetamol in Denmark, which is part of the European Union regulatory framework. The approval was announced via a Regulation 30 disclosure to the exchanges. No financial details, order values, or revenue projections were disclosed in the filing.
This is a positive regulatory milestone that opens the door for Medicamen to enter or expand in the European market through its Danish partner. However, since no revenue figures or order volumes were shared, the immediate financial impact on shareholders remains unclear.